Spruce Biosciences, Inc. (SPRB): EBITDA
-$36.49M
Year ended 2025-12-31
-$46.94M
Trailing 12 months to 2026-06-30
| Period ended | EBITDA | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | -$36.49M | n/m | 2026-03-09, From 2025-01-01 |
| 2024-12-31 | -$56.10M | n/m | 2026-03-09, From 2024-01-01 |
| 2023-12-31 | -$51.92M | n/m | 2025-04-15, From 2023-01-01 |
| 2022-12-31 | -$47.21M | n/m | 2024-03-18, From 2022-01-01 |
| 2021-12-31 | -$42.00M | n/m | 2023-03-16, From 2021-01-01 |
| 2020-12-31 | -$29.38M | n/m | 2022-03-14, From 2020-01-01 |
| 2019-12-31 | -$13.10M | n/a | 2021-03-22, From 2019-01-01 |
EBITDA at similar companies
| Company | Year ended | EBITDA | Change YoY |
|---|---|---|---|
| Spruce Biosciences, Inc. (SPRB) | 2025-12-31 | -$36.49M | n/m |
| TherapeuticsMD, Inc. (TXMD) | 2025-12-31 | -$4.01M | n/m |
| Nature's Sunshine Products Inc (NATR) | 2025-12-31 | $38.59M | +12.5% |
| Lisata Therapeutics, Inc. (LSTA) | 2025-12-31 | -$18.06M | n/m |
| Heron Therapeutics, Inc. (HRTX) | 2025-12-31 | -$224.0K | n/m |
| Teva Pharmaceutical Industries Ltd (TEVA) | 2025-12-31 | $3.16B | +317.9% |
| Emmaus Life Sciences, Inc. (EMMA) | 2025-12-31 | $270.0K | n/m |
| GeoVax Labs, Inc. (GOVX) | 2025-12-31 | -$21.57M | n/m |
| Lifevantage Corp (LFVN) | 2026-06-30 | $8.87M | -42.2% |
Compare SPRB, TXMD, NATR, LSTA side by side · Screen every company in Pharmaceutical Preparations ↗